Kevin Daly college bursary program opens in Canada to help ALS families

ATH-1105 prolongs survival in mouse model of ALS

ATH-1105, a treatment candidate by Athira Pharma, significantly prolonged survival in a mouse model of amyotrophic lateral sclerosis (ALS), according to a company update. Consistent with previous analyses, the treatment also reduced neurodegeneration, inflammation, and the toxic buildup of the TDP-43 protein in nerve cells, which resulted…

Improving ALS, FTD research is aim of digital tool grant program

The ALS Association and the Association for Frontotemporal Degeneration (AFTD) have opened a global grant program to accelerate the development of digital assessment tools for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), a related condition. The Digital Assessment Tools for FTD and ALS Awards, backed…

I’m promoting a different kind of ALS awareness this month

I love learning about all the great activities happening during ALS Awareness Month, but I also worry that we’re attracting the attention of unscrupulous health advocates and clinics who target vulnerable ALS patients and their families. My health-fraud antenna is on high alert. Spending 30 years managing the…

Wearable Cognixion ONE Axon named FDA breakthrough device

Cognixion’s flagship device Cognixion ONE Axon, a product designed to improve communication in people with severe motor impairments, has beed granted breakthrough device designation by the U.S. Food and Drug Administration (FDA). The wireless device is specifically designed for people with people with amyotrophic lateral sclerosis (ALS)…